Literature DB >> 28410914

Occult hepatitis B infection reactivation after ruxolitinib therapy.

Giovanni Perricone1, Maria Vinci2, Ester Pungolino3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28410914     DOI： 10.1016/j.dld.2017.03.004

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN： 1590-8658            Impact factor:   4.088


× No keyword cloud information.
  3 in total

Review 1.  Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).

Authors:  Georg Maschmeyer; Julien De Greef; Sibylle C Mellinghoff; Annamaria Nosari; Anne Thiebaut-Bertrand; Anne Bergeron; Tomas Franquet; Nicole M A Blijlevens; Johan A Maertens
Journal:  Leukemia       Date:  2019-01-30       Impact factor: 11.528

Review 2.  Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors.

Authors:  Daniele Cattaneo; Alessandra Iurlo
Journal:  Front Immunol       Date:  2021-11-19       Impact factor: 7.561

3.  HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?

Authors:  Elisa Gremese; Antonio Gasbarrini; Gianfranco Ferraccioli
Journal:  RMD Open       Date:  2020-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.